| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Vitamin D Deficiency | 3 | 2017 | 1782 | 0.75 | Why? |
| Expectorants | 1 | 2018 | 95 | 0.71 | Why? |
| Central Venous Pressure | 1 | 2017 | 24 | 0.71 | Why? |
| Tuberculosis, Miliary | 1 | 2018 | 66 | 0.70 | Why? |
| Water-Electrolyte Imbalance | 1 | 2018 | 119 | 0.69 | Why? |
| Fever of Unknown Origin | 1 | 2018 | 93 | 0.68 | Why? |
| Cryptococcosis | 1 | 2018 | 97 | 0.68 | Why? |
| Cryptosporidium | 1 | 2017 | 46 | 0.67 | Why? |
| Cryptosporidiosis | 1 | 2017 | 46 | 0.66 | Why? |
| Intensive Care Units, Pediatric | 7 | 2020 | 1098 | 0.66 | Why? |
| Bronchitis | 1 | 2018 | 146 | 0.66 | Why? |
| Vena Cava, Inferior | 1 | 2017 | 103 | 0.64 | Why? |
| Acetylcysteine | 1 | 2018 | 255 | 0.60 | Why? |
| Health Status Indicators | 1 | 2019 | 341 | 0.59 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2018 | 952 | 0.58 | Why? |
| Muscle Weakness | 1 | 2017 | 406 | 0.54 | Why? |
| Child Health Services | 1 | 2021 | 520 | 0.54 | Why? |
| Fluid Therapy | 1 | 2018 | 628 | 0.52 | Why? |
| Vitamin D | 4 | 2017 | 2904 | 0.51 | Why? |
| Pneumonia, Ventilator-Associated | 2 | 2018 | 861 | 0.50 | Why? |
| Airway Obstruction | 1 | 2015 | 182 | 0.49 | Why? |
| Child | 36 | 2021 | 70012 | 0.46 | Why? |
| Acute Lung Injury | 1 | 2020 | 904 | 0.45 | Why? |
| India | 20 | 2021 | 11875 | 0.39 | Why? |
| Infant | 20 | 2021 | 30274 | 0.39 | Why? |
| Sepsis | 4 | 2019 | 3517 | 0.38 | Why? |
| Child, Preschool | 22 | 2020 | 36283 | 0.38 | Why? |
| Dengue | 2 | 2019 | 1565 | 0.35 | Why? |
| Disaster Planning | 1 | 2020 | 1680 | 0.33 | Why? |
| Critical Illness | 4 | 2018 | 17281 | 0.33 | Why? |
| Liver Failure, Acute | 1 | 2010 | 279 | 0.32 | Why? |
| HIV-1 | 3 | 2018 | 3365 | 0.31 | Why? |
| Palliative Care | 1 | 2020 | 2665 | 0.29 | Why? |
| Diarrhea | 1 | 2017 | 2743 | 0.28 | Why? |
| Cystic Fibrosis | 3 | 2020 | 1104 | 0.28 | Why? |
| Asthma | 3 | 2017 | 4383 | 0.27 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.26 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.23 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.20 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.20 | Why? |
| Skin Physiological Phenomena | 1 | 2019 | 27 | 0.20 | Why? |
| Respiration, Artificial | 4 | 2020 | 22116 | 0.19 | Why? |
| Mother-Child Relations | 1 | 2021 | 148 | 0.19 | Why? |
| Antitubercular Agents | 3 | 2017 | 775 | 0.19 | Why? |
| Humans | 58 | 2021 | 930598 | 0.19 | Why? |
| Citrate (si)-Synthase | 1 | 2018 | 10 | 0.19 | Why? |
| Health Impact Assessment | 1 | 2020 | 181 | 0.19 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.19 | Why? |
| Infant, Newborn | 11 | 2020 | 23105 | 0.19 | Why? |
| Bartonella Infections | 1 | 2018 | 18 | 0.18 | Why? |
| Bartonella henselae | 1 | 2018 | 28 | 0.18 | Why? |
| HIV Infections | 5 | 2018 | 11620 | 0.18 | Why? |
| Cryptococcus neoformans | 1 | 2018 | 71 | 0.18 | Why? |
| Infusions, Intraosseous | 1 | 2018 | 36 | 0.18 | Why? |
| Phosphorus | 1 | 2017 | 80 | 0.17 | Why? |
| Tibia | 1 | 2018 | 72 | 0.17 | Why? |
| Nitroimidazoles | 1 | 2017 | 69 | 0.17 | Why? |
| Oxazoles | 1 | 2017 | 75 | 0.17 | Why? |
| Diarylquinolines | 1 | 2017 | 90 | 0.16 | Why? |
| Immunocompetence | 1 | 2018 | 280 | 0.16 | Why? |
| CD4 Lymphocyte Count | 3 | 2017 | 1517 | 0.16 | Why? |
| Raynaud Disease | 1 | 2017 | 86 | 0.16 | Why? |
| Parathyroid Hormone | 1 | 2016 | 98 | 0.16 | Why? |
| Respiratory Muscles | 1 | 2017 | 116 | 0.16 | Why? |
| Coronavirus | 3 | 2020 | 18339 | 0.16 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.16 | Why? |
| Vascular Access Devices | 1 | 2018 | 122 | 0.16 | Why? |
| Gastroesophageal Reflux | 1 | 2017 | 124 | 0.16 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.16 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.16 | Why? |
| Respiratory Insufficiency | 1 | 2017 | 7301 | 0.16 | Why? |
| B-Lymphocyte Subsets | 1 | 2018 | 372 | 0.16 | Why? |
| Adolescent | 14 | 2020 | 86841 | 0.15 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.15 | Why? |
| Arthralgia | 1 | 2017 | 173 | 0.15 | Why? |
| Infant Mortality | 1 | 2017 | 268 | 0.15 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.15 | Why? |
| Health Resources | 2 | 2020 | 2592 | 0.14 | Why? |
| Pseudomonas Infections | 1 | 2020 | 425 | 0.14 | Why? |
| Sarcoidosis | 1 | 2019 | 271 | 0.14 | Why? |
| Bronchoalveolar Lavage | 1 | 2018 | 603 | 0.14 | Why? |
| Cross Protection | 1 | 2017 | 373 | 0.14 | Why? |
| Urokinase-Type Plasminogen Activator | 1 | 2015 | 62 | 0.14 | Why? |
| Tuberculosis | 3 | 2017 | 2895 | 0.14 | Why? |
| Empyema, Pleural | 1 | 2015 | 46 | 0.14 | Why? |
| Pulmonary Aspergillosis | 1 | 2020 | 408 | 0.14 | Why? |
| Breath Tests | 1 | 2017 | 338 | 0.14 | Why? |
| Picornaviridae Infections | 1 | 2020 | 544 | 0.14 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.14 | Why? |
| Exhalation | 1 | 2017 | 441 | 0.13 | Why? |
| Capacity Building | 1 | 2020 | 683 | 0.13 | Why? |
| Policy Making | 1 | 2021 | 829 | 0.13 | Why? |
| Pulmonary Medicine | 1 | 2020 | 706 | 0.13 | Why? |
| Zinc | 2 | 2018 | 817 | 0.13 | Why? |
| B-Lymphocytes | 2 | 2019 | 4418 | 0.13 | Why? |
| Arthritis | 1 | 2017 | 288 | 0.13 | Why? |
| Metabolome | 1 | 2017 | 624 | 0.13 | Why? |
| Monitoring, Physiologic | 2 | 2017 | 1956 | 0.13 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.13 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.12 | Why? |
| Female | 30 | 2021 | 380317 | 0.12 | Why? |
| Shock | 1 | 2020 | 1868 | 0.12 | Why? |
| Airway Extubation | 1 | 2017 | 403 | 0.12 | Why? |
| Organ Dysfunction Scores | 1 | 2019 | 1475 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.12 | Why? |
| Administration, Inhalation | 1 | 2018 | 1647 | 0.12 | Why? |
| Lymphadenopathy | 1 | 2018 | 444 | 0.11 | Why? |
| Tuberculosis, Pulmonary | 2 | 2020 | 1171 | 0.11 | Why? |
| Dengue Virus | 1 | 2019 | 910 | 0.11 | Why? |
| Male | 27 | 2020 | 367725 | 0.11 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.11 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.11 | Why? |
| Bronchoscopy | 2 | 2018 | 991 | 0.11 | Why? |
| Scleroderma, Systemic | 1 | 2017 | 583 | 0.11 | Why? |
| Hospitals, Teaching | 1 | 2019 | 1609 | 0.11 | Why? |
| Software Design | 1 | 2010 | 87 | 0.11 | Why? |
| Radiography | 1 | 2018 | 1576 | 0.10 | Why? |
| Hepatic Encephalopathy | 1 | 2010 | 88 | 0.10 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.10 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Intracranial Hypertension | 1 | 2010 | 111 | 0.09 | Why? |
| Sputum | 1 | 2017 | 1720 | 0.09 | Why? |
| Shock, Septic | 1 | 2019 | 1313 | 0.09 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.09 | Why? |
| Hepatitis A | 1 | 2010 | 140 | 0.09 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.09 | Why? |
| Respiratory Tract Infections | 2 | 2020 | 6817 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.09 | Why? |
| Perinatal Mortality | 1 | 2008 | 120 | 0.09 | Why? |
| Congenital Abnormalities | 1 | 2009 | 170 | 0.08 | Why? |
| Bacterial Infections | 2 | 2017 | 2229 | 0.08 | Why? |
| Follow-Up Studies | 4 | 2020 | 17020 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.08 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2008 | 260 | 0.08 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.08 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.08 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.07 | Why? |
| Epitopes | 1 | 2017 | 4113 | 0.07 | Why? |
| Pediatrics | 1 | 2020 | 2969 | 0.07 | Why? |
| Prospective Studies | 6 | 2018 | 43301 | 0.07 | Why? |
| Oxygen | 1 | 2018 | 3715 | 0.07 | Why? |
| Oxygen Inhalation Therapy | 1 | 2018 | 3629 | 0.07 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.07 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.07 | Why? |
| Hospital Mortality | 2 | 2018 | 22087 | 0.07 | Why? |
| Developing Countries | 2 | 2017 | 4283 | 0.07 | Why? |
| Lung Diseases | 1 | 2018 | 2361 | 0.07 | Why? |
| Reproductive Techniques, Assisted | 1 | 2009 | 400 | 0.07 | Why? |
| Treatment Outcome | 7 | 2019 | 51732 | 0.07 | Why? |
| Protease Inhibitors | 1 | 2020 | 3630 | 0.07 | Why? |
| Zoonoses | 1 | 2018 | 3034 | 0.06 | Why? |
| Tertiary Care Centers | 5 | 2020 | 8248 | 0.06 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.06 | Why? |
| Length of Stay | 2 | 2018 | 11042 | 0.06 | Why? |
| Immunosuppressive Agents | 2 | 2019 | 6331 | 0.06 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.06 | Why? |
| ROC Curve | 3 | 2019 | 6024 | 0.06 | Why? |
| Antibodies, Neutralizing | 2 | 2019 | 25288 | 0.05 | Why? |
| Burkholderia cepacia complex | 1 | 2020 | 18 | 0.05 | Why? |
| Lung Diseases, Parasitic | 1 | 2020 | 17 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.05 | Why? |
| Pseudomonas | 1 | 2020 | 65 | 0.05 | Why? |
| Burkholderia Infections | 1 | 2020 | 33 | 0.05 | Why? |
| Aspergillus flavus | 1 | 2020 | 51 | 0.05 | Why? |
| Severe Acute Respiratory Syndrome | 2 | 2020 | 12361 | 0.05 | Why? |
| Diagnostic Techniques, Respiratory System | 1 | 2020 | 114 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.05 | Why? |
| Hemosiderosis | 1 | 2018 | 13 | 0.05 | Why? |
| Clinical Protocols | 1 | 2010 | 2734 | 0.05 | Why? |
| Cranial Fontanelles | 1 | 2017 | 3 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Cat-Scratch Disease | 1 | 2018 | 17 | 0.05 | Why? |
| Candida albicans | 1 | 2020 | 217 | 0.04 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.04 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Sweat | 1 | 2019 | 127 | 0.04 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.04 | Why? |
| Infant Formula | 1 | 2017 | 64 | 0.04 | Why? |
| Adult | 6 | 2020 | 244371 | 0.04 | Why? |
| Absorptiometry, Photon | 1 | 2017 | 168 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2019 | 265 | 0.04 | Why? |
| Blood Coagulation Disorders | 1 | 2010 | 2040 | 0.04 | Why? |
| Milk | 1 | 2017 | 158 | 0.04 | Why? |
| Nebulizers and Vaporizers | 1 | 2020 | 497 | 0.04 | Why? |
| Serogroup | 1 | 2019 | 510 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.04 | Why? |
| Candidiasis | 1 | 2020 | 334 | 0.04 | Why? |
| Anti-HIV Agents | 1 | 2008 | 2209 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2019 | 51949 | 0.04 | Why? |
| HIV Envelope Protein gp120 | 1 | 2017 | 267 | 0.04 | Why? |
| Embolization, Therapeutic | 1 | 2018 | 269 | 0.04 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.04 | Why? |
| Methotrexate | 1 | 2019 | 471 | 0.03 | Why? |
| Pseudomonas aeruginosa | 1 | 2020 | 652 | 0.03 | Why? |
| Liver Transplantation | 1 | 2010 | 2864 | 0.03 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.03 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.03 | Why? |
| Lung | 2 | 2020 | 31049 | 0.03 | Why? |
| Forced Expiratory Volume | 1 | 2017 | 632 | 0.03 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.03 | Why? |
| Thoracic Surgery, Video-Assisted | 1 | 2015 | 97 | 0.03 | Why? |
| Rabbits | 1 | 2018 | 1171 | 0.03 | Why? |
| Calcium Channel Blockers | 1 | 2017 | 367 | 0.03 | Why? |
| Water | 1 | 2019 | 765 | 0.03 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.03 | Why? |
| Quality Control | 1 | 2017 | 628 | 0.03 | Why? |
| Rhinovirus | 1 | 2020 | 979 | 0.03 | Why? |
| Cadaver | 1 | 2018 | 626 | 0.03 | Why? |
| Oximetry | 1 | 2018 | 658 | 0.03 | Why? |
| Tertiary Healthcare | 1 | 2017 | 616 | 0.03 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2008 | 4545 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2017 | 657 | 0.03 | Why? |
| Infant, Premature | 1 | 2018 | 883 | 0.03 | Why? |
| Critical Care | 1 | 2017 | 14081 | 0.03 | Why? |
| Cattle | 1 | 2017 | 1336 | 0.03 | Why? |
| Staphylococcus aureus | 1 | 2020 | 844 | 0.03 | Why? |
| Global Burden of Disease | 1 | 2017 | 531 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| United States | 1 | 2020 | 46150 | 0.03 | Why? |
| Intensive Care Units, Neonatal | 1 | 2018 | 749 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.03 | Why? |
| Epitope Mapping | 1 | 2017 | 1240 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2020 | 1061 | 0.03 | Why? |
| Metabolomics | 1 | 2017 | 921 | 0.03 | Why? |
| Cats | 1 | 2018 | 1890 | 0.03 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2008 | 5164 | 0.03 | Why? |
| Recurrence | 1 | 2020 | 3675 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Airway Management | 1 | 2020 | 1298 | 0.03 | Why? |
| Mycobacterium tuberculosis | 1 | 2020 | 1164 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.03 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2020 | 1099 | 0.03 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.03 | Why? |
| Intensive Care Units | 1 | 2017 | 29594 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.02 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Incidence | 3 | 2018 | 25622 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2017 | 1530 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.02 | Why? |
| Thorax | 1 | 2017 | 1873 | 0.02 | Why? |
| Noninvasive Ventilation | 1 | 2020 | 2329 | 0.02 | Why? |
| Cross Reactions | 1 | 2019 | 4374 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2020 | 3129 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.02 | Why? |
| Skin | 1 | 2019 | 2096 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.02 | Why? |
| Dietary Supplements | 1 | 2018 | 2251 | 0.02 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Quality of Health Care | 1 | 2017 | 1948 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.02 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.02 | Why? |
| Viruses | 1 | 2017 | 2238 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.02 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2008 | 11559 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Perinatal Care | 1 | 2008 | 576 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2019 | 6537 | 0.01 | Why? |
| Machine Learning | 1 | 2017 | 4395 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Emergency Medical Services | 1 | 2018 | 3557 | 0.01 | Why? |
| Primary Prevention | 1 | 2008 | 778 | 0.01 | Why? |
| Global Health | 2 | 2021 | 13911 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.01 | Why? |
| Comorbidity | 2 | 2017 | 34796 | 0.01 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.01 | Why? |
| Animals | 2 | 2018 | 78931 | 0.01 | Why? |
| Radiography, Thoracic | 1 | 2015 | 5486 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Pregnancy | 2 | 2009 | 23879 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
| Middle Aged | 2 | 2018 | 270681 | 0.01 | Why? |
| Communicable Diseases, Emerging | 1 | 2003 | 2523 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2018 | 88759 | 0.01 | Why? |
| Travel | 1 | 2003 | 7220 | 0.00 | Why? |
| Aged | 1 | 2018 | 215776 | 0.00 | Why? |